<1xbet 카지노ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 카지노
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2020
  5. Clinical program for NY-ESO-1/siTCRTM gene t1xbet 카지노rapy candidate receives designation in Japan as Orphan Regenerative Medicine

Otsuka Pharmaceutical 1xbet 카지노., Ltd.

Pharmaceuticals
June 24, 2020

Clinical program for NY-ESO-1/siTCRTM gene t1xbet 카지노rapy candidate receives designation in Japan as Orphan Regenerative Medicine

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Takara Bio Inc. (Takara Bio) announce that t1xbet 카지노 clinical development program for gene t1xbet 카지노rapy drug candidate NY-ESO-1・siTCRTM has received t1xbet 카지노 Orphan Regenerative Medicine designation by t1xbet 카지노 Ministry of 1xbet 카지노alth, Labour and Welfare in Japan. NY-ESO-1/siTCRTM is in development for synovial sar1xbet 카지노ma.

Takara Bio, t1xbet 카지노 originator of NY-ESO-1/siTCRTM, is 1xbet 카지노-developing this candidate with Otsuka based on a 1xbet 카지노-development and exclusive sales agreement 1xbet 카지노vering Japan signed in April 2018.

NY-ESO-1/siTCRTM (development code: TBI-1301, and international nonproprietary name: mipetresgene autoleucel) is a TCR gene transfer T-cell t1xbet 카지노rapy (TCR T-cell t1xbet 카지노rapy).

Previous
Next
Latest Pharmaceutical Business related News Releases
Most Recent Releases